SETD2

Across TCGA pan-cancer cohorts, SETD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SETD2 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SETD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SETD2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where SETD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.206	0.413	.006	19	view →
HNSC	OS	Quartile	All	0.780	0.904	.011	16	view →
LSCC	OS	Tertile	All	0.926	0.708	.013	9	view →
LUAD	OS	Median	II,III,IV	0.751	0.508	.029	6	view →
UCEC	DFS	Median	All	0.852	0.953	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SETD2–PDAC (DFS)

Open the PDAC breakdown →